1. Background {#sec128403}
=============

Shiga toxigenic *Escherichia coli* (STEC) is a significant cause of gastrointestinal disease, diarrhea, bloody diarrhea, hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura, hemolytic anemia, hemorrhagic colitis (HC) and acute renal failure in humans ([@A29706R1]-[@A29706R3]). It has been estimated that the STEC strains are one of the most prevalent causes of mortality in pediatrics ([@A29706R3]-[@A29706R6]). To appraise the pathogenicity of STEC strains, assessment of latent virulence factors is a pre-requisite. The factors that are most frequently associated with STEC infections and diarrhea are Shiga toxins (*stx1 and stx2*), intimin (*eaeA*) and hemolysin (*hlyA*) ([@A29706R1]-[@A29706R3], [@A29706R7]). Most outbreaks and sporadic cases of bloody and non-bloody diarrhea, HUS and even HC have been attributed to the O157 serogroup of the STEC strains. In line with this, the roles of non-O157 serogroups like O111, O103, O26, O145, O113, O45, O121, O91 and O128 have been recognized as causes of HUS, HC, bloody and non-bloody diarrhea and other gastrointestinal disorders ([@A29706R1], [@A29706R2], [@A29706R8], [@A29706R9]). In addition to O-serogroups and virulence factors, treatment is a critical point to assess the epidemiological contents of STEC strains in the cases of diarrhea, while therapeutic options have become somewhat limited because of the presence of multi drug resistant strains of these bacteria ([@A29706R1]-[@A29706R3], [@A29706R10]). Antibiotic resistant strains of STEC can cause more severe diseases in humans and animals. Antibiotic resistance in STEC strains is associated with the presences of some antibiotic resistance genes ([@A29706R1]-[@A29706R3], [@A29706R10]). The genes that encode resistance against tetracycline (*tetA* and *tetB*), trimethoprim (*dfrA1*), aminoglycosides (*aadA1*), fluoroquinolone (*qnr*), gentamicin (*aac(3)-IV*), sulfonamide (*sul1*), cephalothin (*blaSHV*), ampicillin (*CITM*), erythromycin (*ereA*) and chloramphenicol (*cat1* and *cmlA*) are the most commonly detected antibiotic resistance genes in the resistant isolates of STEC strains ([@A29706R1]-[@A29706R3], [@A29706R10]). Based on Iranian epidemiological researches, STEC strains have been known as the most commonly detected pathogens in pediatric patients with diarrhea and show a high incidence of resistance (85 - 100%) against commonly used antimicrobial agents ([@A29706R3], [@A29706R11], [@A29706R12]).

Imperious data about the prevalence of O-serogroups, virulence factors and antibiotic resistance properties in STEC strains isolated from pediatric patients are rare in Iran.

2. Objectives {#sec128404}
=============

The present research was carried out in order to study the distribution of virulence factors, O-serogroups, antibiotic resistance genes and pattern of antibiotic resistance of STEC strains isolated from diarrheic and non-diarrheic pediatric patients with respect to the role of season, age and geographical area of sample collection.

3. Patients and Methods {#sec128411}
=======================

3.1. Samples and Escherichia coli Identification {#sec128405}
------------------------------------------------

From January 2014 to January 2015 during various seasons of the year, a total of 480 stool samples from diarrheic (n = 200) and non-diarrheic (n = 280) pediatric patients were collected from educational hospitals of various provinces of Iran. Individuals of the diarrheic group were classified into six groups based on their age (less than a month old, 1 - 10 months, 11 - 21 months, 22 - 33 months, 34 - 45 months, 46 - 57 months and 58 - 69 months old). Clinical histories of pediatric patients were obtained through questionnaires. Stool specimens were collected using sterile rectal swabs. All swabs were placed in tubes containing Stuart medium. Samples were transferred to the laboratory at 4°C in a cooler with iced-packs.

All samples were diluted using phosphate buffer saline (PBS, Merck, Germany). Samples were then plated onto MacConkey's agar (MC, Merck, Germany) and incubated overnight at 37°C. From each sample, a typical lactose positive colony was selected and placed onto eosin methylene blue (EMB; Merck, Germany) and incubated overnight at 37°C. Metallic green colonies were considered as typical *E. coli* colonies. *Escherichia coli* isolates were also characterized by evaluation of standard biochemical tests including Indole, Methyl red, Voges-Proskauer, Triple Sugar Iron agar (TSI; Merck, Germany), urease, lysine decarboxylase and citrate utilization. Colonies were further confirmed to be *E. coli* using the polymerase chain reaction (PCR) ([@A29706R13]).

3.2. Antimicrobial Susceptibility Testing {#sec128406}
-----------------------------------------

Antimicrobial susceptibility of *E. coli* isolates was determined by the Kirby-Bauer disc diffusion method using Mueller-Hinton agar (Merck, Germany), according to the Clinical and Laboratory Standards Institute guidelines (CLSI 2012). After incubating the inoculated plate aerobically at 37°C for 18 - 24 hours in an aerobic atmosphere, the susceptibility of the *E. coli* isolates to tetracycline (30 µg/disk), chloramphenicol (30 µg/disk), sulfamethoxazole (25 µg/disk), gentamycin (10 µg/disk), cephalothin (30 µg/disk), trimethoprim (5 µg/disk), ciprofloxacin (5 µg/disk), ampicillin (10 u/disk), co-trimoxazole (25 µg/disk), cefotaxime (30 µg), ceftriaxone (30 µg), cefixime (5 µg), nalidixic acid (30 µg) and norfloxacin (10 µg) antimicrobial agents was measured and the results were interpreted in accordance with interpretive criteria provided by CLSI (CLSI 2012). *Escherichia coli* ATCC 35218 was used as the quality control organism in antimicrobial susceptibility determination.

3.3. DNA Extraction {#sec128407}
-------------------

Total genomic DNA was extracted from the bacterial colonies. A single colony was inoculated on trypticase soy agar (TSA, Merck, Germany) and incubated over night at 37ºC. Next, 1.5 mL of a saturated culture was harvested with centrifugation for five minutes, at 14000 rpm. The cell pellet was resuspended and lysed in 200 µL of lysis buffer (40 mM tris-acetate, pH 7.8, 20 mM sodium-acetate, 1 mM EDTA, 1% SDS) by vigorous pipetting. To remove most proteins and cell debris, 66 µL of 5 M NaCl solution was added and mixed well, and then the viscous mixture was centrifuged at 12000 rpm for 10 minutes at 4ºC. After transferring the clear supernatant to a new eppendorf tube, an equal volume of chloroform was added, and the tube was gently inverted at least 50 times when a milky solution was completely formed. Following centrifugation at 14000 rpm for five minutes, the supernatant was transferred to another eppendorf tube and double volume of 100% ethanol was added. The tubes were gently inverted five to six times, then centrifuged at 10000 rpm for five minutes. The supernatant was discarded and 1 ml of ethanol (70%) was added to the pellet, and tubes were centrifuged at 10000 rpm for five minutes. Finally, the supernatant was discarded and the pellet was dried for 10 minutes at room temperature, and the pellet was resuspended by 100 µL of H~2~O. The stock was kept at -20ºC until use. The DNA concentration was determined by measuring absorbance of the sample at 260 nm using a spectrophotometer ([@A29706R14]).

3.4. Detection of Serogroups, Virulence Factors and Antibiotic Resistance Genes {#sec128408}
-------------------------------------------------------------------------------

The oligonucleotide primers and PCR program used for detection of O-serogroups, virulence factors and antibiotic resistance genes of *E. coli* isolates are shown in [Table 1](#tbl33237){ref-type="table"}. All PCR reactions were amplified in a programmable thermal cycler (Eppendorf, Mastercycler® 5330, Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany) PCR device. Finally, 15 µL of PCR products were resolved on a 1.5% agarose gel containing 0.5 mg/mL of ethidium bromide in tris--borate-- Ethylenediaminetetraacetic acid (EDTA) buffer at 90 V for one hour, using suitable molecular weight markers. The products were examined under ultraviolet illumination. Strains of *E. coli* O157: K88ac: H19, CAPM 5933 and *E. coli* O159: H20, CAPM 6006 were used as positive controls and distilled water was used as the negative control.

###### The Oligonucleotide Primers and the Polymerase Chain Reaction Programs Used for Amplification of O-Serogroups, Virulence Factors and Antibiotic Resistance Genes of *Escherichia coli* Isolates From Pediatric Patients With and Without Diarrhea

  Target Gene                                                     Primer Sequence (5\' - 3\') ^[a](#fn34863){ref-type="table-fn"}^   PCR Product, bp
  --------------------------------------------------------------- ------------------------------------------------------------------ -----------------
  **O157** ^**[b](#fn34864){ref-type="table-fn"}**^               F: CGGACATCCATGTGATATGG                                            259
  R: TTGCCTATGTACAGCTAATCC                                                                                                           
  **O145** ^**[b](#fn34864){ref-type="table-fn"}**^               F: CCATCAACAGATTTAGGAGTG                                           609
  R: TTTCTACCGCGAATCTATC                                                                                                             
  **O103** ^**[b](#fn34864){ref-type="table-fn"}**^               F: TTGGAGCGTTAACTGGACCT                                            321
  R: GCTCCCGAGCACGTATAAG                                                                                                             
  **O26** ^**[b](#fn34864){ref-type="table-fn"}**^                F: CAGAATGGTTATGCTACTGT                                            423
  R: CTTACATTTGTTTTCGGCATC                                                                                                           
  **O111** ^**[b](#fn34864){ref-type="table-fn"}**^               F: TAGAGAAATTATCAAGTTAGTTCC                                        406
  R: ATAGTTATGAACATCTTGTTTAGC                                                                                                        
  **O91** ^**[c](#fn34865){ref-type="table-fn"}**^                F: GCTGACCTTCATGATCTGTTGA                                          291
  R: TAATTTAACCCGTAGAATCGCTGC                                                                                                        
  **O128** ^**[c](#fn34865){ref-type="table-fn"}**^               F: GCTTTCTGCCGATATTTGGC                                            289
  R: CCGACGGACTGATGCCGGTGATT                                                                                                         
  **O121** ^**[c](#fn34865){ref-type="table-fn"}**^               F: TGGCTAGTGGCATTCTGATG                                            322
  R: TGATACTTTAGCCGCCCTTG                                                                                                            
  **O113** ^**[c](#fn34865){ref-type="table-fn"}**^               F: GGGTTAGATGGAGCGCTATTGAGA                                        771
  R: AGGTCACCCTCTGAATTATGGCAG                                                                                                        
  **O45** ^**[c](#fn34865){ref-type="table-fn"}**^                F: CCGGGTTTCGATTTGTGAAGGTTG                                        527
  R: CACAACAGCCACTACTAGGCAGAA                                                                                                        
  ***stx1*** ^**[d](#fn34866){ref-type="table-fn"}**^             F: AAATCGCCATTCGTTGACTACTTCT                                       366
  R: TGCCATTCTGGCAACTCGCGATGCA                                                                                                       
  ***stx2*** ^**[d](#fn34866){ref-type="table-fn"}**^             F: CGATCGTCACTCACTGGTTTCATCA                                       282
  R: GGATATTCTCCCCACTCTGACACC                                                                                                        
  ***eaeA*** ^**[d](#fn34866){ref-type="table-fn"}**^             F: TGCGGCACAACAGGCGGCGA                                            629
  R: CGGTCGCCGCACCAGGATTC                                                                                                            
  ***ehly*** ^**[d](#fn34866){ref-type="table-fn"}**^             F: CAATGCAGATGCAGATACCG                                            432
  R: CAGAGATGTCGTTGCAGCAG                                                                                                            
  ***aadA1*** ^**[e](#fn34867){ref-type="table-fn"}**^            F: TATCCAGCTAAGCGCGAACT                                            447
  R: ATTTGCCGACTACCTTGGTC                                                                                                            
  ***tetA*** ^**[e](#fn34867){ref-type="table-fn"}**^             F: GGTTCACTCGAACGACGTCA                                            577
  R: CTGTCCGACAAGTTGCATGA                                                                                                            
  ***tetB*** ^**[e](#fn34867){ref-type="table-fn"}**^             F: CCTCAGCTTCTCAACGCGTG                                            634
  R: GCACCTTGCTGATGACTCTT                                                                                                            
  ***dfrA1*** ^**[e](#fn34867){ref-type="table-fn"}**^            F: GGAGTGCCAAAGGTGAACAGC                                           367
  R: GAGGCGAAGTCTTGGGTAAAAAC                                                                                                         
  ***qnr*** ^**[e](#fn34867){ref-type="table-fn"}**^              F: GGGTATGGATATTATTGATAAAG                                         670
  R: CTAATCCGGCAGCACTATTTA                                                                                                           
  ***aac(3)-IV sul1*** ^**[e](#fn34867){ref-type="table-fn"}**^   F: CTTCAGGATGGCAAGTTGGT                                            286
  R: TCATCTCGTTCTCCGCTCAT                                                                                                            
  ***blaSHV*** ^**[e](#fn34867){ref-type="table-fn"}**^           F: TTCGGCATTCTGAATCTCAC                                            822
  R: ATGATCTAACCCTCGGTCTC                                                                                                            
  ***CITM*** ^**[e](#fn34867){ref-type="table-fn"}**^             F: TCGCCTGTGTATTATCTCCC                                            768
  R: CGCAGATAAATCACCACAATG                                                                                                           
  ***cat1*** ^**[e](#fn34867){ref-type="table-fn"}**^             F: TGGCCAGAACTGACAGGCAAA                                           462
  R: TTTCTCCTGAACGTGGCTGGC                                                                                                           
  ***cmlA*** ^**[e](#fn34867){ref-type="table-fn"}**^             F: AGTTGCTCAATGTACCTATAACC                                         547
  R: TTGTAATTCATTAAGCATTCTGCC                                                                                                        
  ***aadA1*** ^**[e](#fn34867){ref-type="table-fn"}**^            F: CCGCCACGGTGTTGTTGTTATC                                          698
  R: CACCTTGCCTGCCCATCATTAG                                                                                                          

^a^The oligonucleotide primers and PCR programs were obtained from previous studies.

^b^PCR Program: 1 cycle: 95°C, 3 minutes. 30 cycles: 95°C, 20 seconds; 58°C, 40 seconds; 72°C , 30 seconds. 1 cycle: 72°C, 8 minutes. PCR Volume (50 μL): 5 μL PCR buffer 10×, 1.5 mM MgCl

^c^PCR Program: 1 cycle: 94°C, 6 minutes. 34 cycle: 95°C, 50 seconds; 58°C, 70 seconds; 72°C, 55 seconds. 1 cycle: 72°C, 10 minutes. PCR Volume (50 μL): 5 μL PCR buffer 10×, 2 mM MgCl

^d^PCR Program: 1 cycle: 95°C, 3 minutes. 34 cycle: 94°C, 60 seconds; 56°C, 45 seconds; 72°C, 60 seconds. 1 cycle: 72°C, 10 minutes. PCR Volume (50 μL): 5 μL PCR buffer 10×, 2 mM MgCl

^e^PCR Program: 1 cycle: 94°C, 8 minutes. 32 cycle: 95°C, 60 seconds; 55°C, 70 seconds; 72°C, 2 minutes. 1 cycle: 72°C, 8 minutes. PCR Volume (50 μL): 5 μL PCR buffer 10×, 2.5 mM MgCl

3.5. Statistical Analysis {#sec128409}
-------------------------

The data were analyzed using the SPSS (statistical package for the social sciences) software and P Value was calculated using the chi-square test to find any significant relationship between various seasons, ages, clinical symptoms and distribution of O-serogroups, virulence genes and antibiotic resistance properties of STEC strains isolated from pediatric patients with and without diarrhea. A P Value of less than 0.05 was considered statistically significant.

3.6. Ethical Issues {#sec128410}
-------------------

The present study was approved by the ethical committee of educational hospitals of Tehran, Isfahan, Shiraz and Mashhad. The life, health, dignity, integrity, rights to self-determination, privacy, and confidentiality of personal information of research subjects were also protected. All patients or their parents signed the written informed consent.

4. Results {#sec128412}
==========

All of the swab samples of pediatric patients with and without diarrhea were studied using the culture method and positive results were confirmed to be *E. coli* by the PCR technique. Age, seasonal and geographical distribution of *E. coli* in the pediatric patients with and without diarrhea are shown in [Table 2](#tbl33238){ref-type="table"}. Of the 480 studied samples, 195 (40.62) samples were positive for *E. coli*. On the other hand, 118 out of 200 diarrheic stool samples (59%) and 77 out of 280 non-diarrheic stool samples (27.5%) were positive. A significant difference was observed between the prevalence of *E. coli* from diarrheic and non-diarrheic patients (P \< 0.027). Overall, 1 - 10 month old patients had the highest incidence of *E. coli* (73.33%) yet 58 - 69 month old patients had the lowest incidence of *E. coli* (38.46%). *Escherichia coli* strains had the highest prevalence in the Shiraz (81.13%), followed by Isfahan (69.56%) and Tehran (50.84%). The swab samples, which were taken in the summer season had the highest prevalence of *E. coli* (91.66%), while those that were taken in the winter season had the lowest prevalence (22.22%). There were significant differences in the incidence of *E. coli* between hot and cold seasons (P = 0.038).

###### Age, Seasonal and Geographical Distribution of *Escherichia coli* in Pediatric Patients With and Without Diarrhea

  Different Criteria              No. Samples Collected   Positive Samples ^[a](#fn34868){ref-type="table-fn"}^
  ------------------------------- ----------------------- -------------------------------------------------------
  **Age distribution, mon**                               
  \< 1                            32                      19 (59.37)
  1 - 10                          30                      22 (73.33)
  11 - 21                         30                      21 (70)
  22 - 33                         27                      16 (59.25)
  34 - 45                         29                      16 (55.17)
  46 - 57                         26                      14 (53.84)
  58 - 69                         26                      10 (38.46)
  **Geographical distribution**                           
  Tehran                          59                      30 (50.84)
  Isfahan                         46                      32 (69.56)
  Shiraz                          53                      43 (81.13)
  Mashhad                         42                      13 (30.95)
  **Seasonal distribution**                               
  Spring                          50                      31 (62)
  Summer                          60                      55 (91.66)
  Autumn                          45                      22 (48.88)
  Winter                          45                      10 (22.22)
  **Total diarrheic samples**     200                     118 (59)
  **Non-diarrheic samples**       280                     77 (27.5)
  **Total**                       480                     195 (40.62)

^a^Data are presented as No. (%).

Total distribution of virulence genes in the *E. coli* subtypes of pediatric patients with and without diarrhea is shown in [Table 3](#tbl33239){ref-type="table"}. *Stx1* and *eaeA* were the most commonly detected virulence factors in the diarrheic and non-diarrheic pediatric patients. The majority of *E. coli* strains harbored *stx1* and *eaeA* genes together, while the prevalence of *E. coli* isolates harboring the *stx2* and *eaeA* factors together were low. The AEEC were the most commonly detected subtype yet EHEC was the least commonly detected. The EHEC subtype was only detected in less than a month (7.69%), 1 - 10 (12.5%) and 34 - 45 (10%) month old pediatric patients. Significant statistical differences were observed between the incidence of *stx1* and *stx2* genes (P = 0.022) and also between the incidence of AEEC and EHEC subtypes (P = 0.031).

###### Total Distribution of Virulence Factors in *Escherichia coli* Subtypes Isolated From Diarrheic and Non-Diarrheic Pediatric Patients^[a](#fn34869){ref-type="table-fn"}^, ^[b](#fn34874){ref-type="table-fn"}^

  Diarrhea Status and Age, mon   No. Positive   Positive     Virulence Factors
  ------------------------------ -------------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------
  **Positive**                                               
  \< 1                           19                          
  Non detected                                  4 (30.76)    \-
  EHEC                                          1 (7.69)     *Stx1*, *eae*, *ehly*: 1 (100)
  AEEC                                          8 (61.53)    *stx1*: 7 (87.5), *stx2*: 3 (37.5), *eaeA*: 5 (62.5), *stx1*, *eaeA*: 4 (50), *stx2*, *eaeA*: 2 (25), *stx1*, *stx2*, *eaeA*: 2 (25)
  Total                                         13 (68.42)   \-
  1 - 10                         22                          
  Non detected                                  5 (31.25)    \-
  EHEC                                          2 (12.5)     *Stx1*, *eae*, *ehly*: 2 (100)
  AEEC                                          9 (56.25)    *stx1*: 8 (88/88), *stx2*: 4 (44.44), *eaeA*: 6 (66.66), *stx1*, *eaeA*: 5 (55.55), *stx2*, *eaeA*: 3 (33.33), *stx1*, *stx2*, *eaeA*: 1 (11.11)
  Total                                         16 (72.72)   \-
  11 - 21                        21                          
  Non detected                                  5 (33.33)    \-
  EHEC                                          \-           *Stx1*, *eae*, *ehly*: -
  AEEC                                          10 (66.66)   *stx1*: 10 (100), *stx2*: 5 (50), *eaeA*: 7 (70), *stx1*, *eaeA*: 6 (60), *stx2*, *eaeA*: 2 (20), *stx1*, *stx2*, *eaeA*: 2 (20)
  Total                                         15 (71.42)   \-
  22 - 33                        16                          
  Non detected                                  4 (36.36)    \-
  EHEC                                          \-           *Stx1*, *eae*, *ehly*: -
  AEEC                                          7 (63.63)    *stx1*: 5 (71.42), *stx2*: 3 (42.85), *eaeA*: 4 (57.14), *stx1*, *eaeA*: 4 (57.14), *stx2*, *eaeA*: 2 (28.57), *stx1*, *stx2*, *eaeA*: 1 (14.28)
  Total                                         11 (68.75)   \-
  34 - 45                        16                          
  Non detected                                  3 (30)       \-
  EHEC                                          1 (10)       *Stx1*, *eae*, *ehly*: 1 (100)
  AEEC                                          6 (60)       *stx1*: 5 (83.33), *stx2*: 2 (33.33), *eaeA*: 4 (66.66), *stx1*, *eaeA*: 3 (50), *stx2*, *eaeA*: 2 (33.33), *stx1*, *stx2*, *eaeA*: 1 (16.66)
  Total                                         10 (62.5)    \-
  46 - 57                        14                          
  Non detected                                  3 (33.33)    \-
  EHEC                                          \-           *Stx1*, *eae*, *ehly*: -
  AEEC                                          6 (66.66)    *stx1*: 6 (100), *stx2*: 2 (33.33), *eaeA*: 5 (83.33), *stx1*, *eaeA*: 4 (66.66), *stx2*, *eaeA*: 1 (16.66), *stx1*, *stx2*, *eaeA*: 1 (16.66)
  Total                                         9 (64.28)    \-
  58 - 69                        10                          
  Non detected                                  2 (33.33)    \-
  EHEC                                          \-           *Stx1*, *eae*, *ehly*: -
  AEEC                                          4 (66.66)    *stx1*: 3 (75.00), *stx2*: 1 (25), *eaeA*: 2 (50), *stx1*, *eaeA*: 2 (50), *stx2*, *eaeA*: 1 (25), *stx1*, *stx2*, *eaeA*: 1 (25)
  Total                                         6 (60)       \-
  **Negative**                   77                          
  Non detected                                  13           \-
  EHEC                                          \-           *Stx1*, *eae*, *ehly*: -
  AEEC                                          12           *stx1*: 10 (83.33), *stx2*: 5 (41.66), *eaeA*: 8 (66.66), *stx1*, *eaeA*: 7 (58.33), *stx2*, *eaeA*: 3 (25), *stx1*, *stx2*, *eaeA*: 2 (16.66)
  Total                                         25 (32.46)   \-

^a^Abbreviations: AEEC: attaching and effacing.

^b^Values are presented as No. (%).

Of the 195 *E. coli* strains, 66 isolates (33.84%) were confirmed to be STEC. Total distribution of O-serogroups in the STEC strains of pediatric patients with and without diarrhea is shown in [Table 4](#tbl33240){ref-type="table"}. We found that the most commonly detected O-serogroups in the diarrheic and non-diarrheic pediatric patients were O26 (33.33%), O111 (18.18%) and O91 (12.12%). There were no positive strains for O157 serogroup in the non-diarrheic pediatric patients. The STEC O-serogroups had the highest incidence in 1 - 10 month old pediatric patients. Significant difference was seen between the age of pediatrics and incidence of STEC O-serogroups (P = 0.043).

###### Total Distribution of O-Serogroups in the Shiga Toxigenic *Escherichia coli* Strains From Pediatric Patients With and Without Diarrhea

  Diarrhea Status and Age, mon   No. STEC Strains   Distribution of O-Serogroups ^[a](#fn34870){ref-type="table-fn"}^                                                                                                
  ------------------------------ ------------------ ------------------------------------------------------------------- ------------ ---------- ------------ ---------- ---------- ----------- ---------- ---------- ----------
  **Positive**                                                                                                                                                                                                       
  \< 1                           9                  1                                                                   3            1          2            \-         \-         1           \-         1          \-
  1 - 10                         11                 2                                                                   4            1          3            \-         \-         1           \-         \-         \-
  11 - 21                        10                 \-                                                                  3            \-         2            1          \-         2           \-         1          1
  22 - 33                        7                  \-                                                                  2            1          1            \-         \-         1           \-         1          1
  34 - 45                        7                  1                                                                   2            1          1            \-         \-         1           \-         1          \-
  46 - 57                        6                  \-                                                                  2            1          1            \-         \-         1           \-         1          \-
  58 - 69                        4                  \-                                                                  1            \-         1            \-         1          1           \-         \-         \-
  **Negative**                   12                 \-                                                                  5            1          1            1          1          \-          1          1          1
  **Total**                      66                 4 (6.06)                                                            22 (33.33)   6 (9.09)   12 (18.18)   2 (3.03)   2 (3.03)   8 (12.12)   1 (1.51)   6 (9.09)   3 (4.54)

^a^Value's unit is %.

Total distribution of antibiotic resistance genes in the STEC strains from pediatric patients with and without diarrhea is shown in [Table 5](#tbl33241){ref-type="table"}. Regarding resistance, *CITM* (80.30%), *aac (3)-IV* (75.75%) and *tetA* (65.15%) were the most commonly detected antibiotic resistance genes in pediatric patients with and without diarrhea. Non-diarrheic pediatric patients had the lowest prevalence of antibiotic resistance genes when compared to diarrheic pediatric. There were no positive results for the *cmlA* gene. A significant difference was seen between the age of pediatric patients and incidence of antibiotic resistance genes (P = 0.035).

###### Total Distribution of Antibiotic Resistance Genes in the Shiga Toxigenic *Escherichia coli* Strains From Pediatric Patients With And Without Diarrhea

  Diarrhea Status and Age, mon   No. STEC Strains   Distribution of Antibiotic Resistance Genes ^[a](#fn34871){ref-type="table-fn"}^                                                                                                                   
  ------------------------------ ------------------ ---------------------------------------------------------------------------------- ------------ ------------ --------- ------------ ------------ ------------ ------------ ------------ ---------- ----
  **Positive**                                                                                                                                                                                                                                         
  \< 1                           9                  3                                                                                  7            2            6         5            8            6            4            8            \-         \-
  1 - 10                         11                 3                                                                                  8            3            6         6            8            7            6            9            \-         \-
  11 - 21                        10                 2                                                                                  6            1            6         6            8            8            5            9            1          \-
  22 - 33                        7                  1                                                                                  5            1            5         4            7            5            3            7            \-         \-
  34 - 45                        7                  1                                                                                  5            2            3         3            6            4            2            6            \-         \-
  46 - 57                        6                  1                                                                                  4            1            3         2            4            3            2            5            \-         \-
  58 - 69                        4                  \-                                                                                 3            \-           2         2            4            3            1            4            1          \-
  **Negative**                   12                 1                                                                                  5            1            2         1            5            2            3            5            \-         \-
  **Total**                      66                 12 (18.18)                                                                         43 (65.15)   11 (16.66)   33 (50)   29 (43.93)   50 (75.75)   38 (57.57)   25 (37.87)   53 (80.30)   2 (3/03)   \-

^a^Values unit is %.

Susceptibility of STEC strains against 14 commonly used antimicrobial agents is shown in [Table 6](#tbl33242){ref-type="table"}. The STEC strains of our study harbored the highest levels of resistance against ampicillin (84.84%), gentamycin (78.78%), tetracycline (50%) and sulfamethoxazole (40.90%) antibiotics. Levels of antibiotic resistance in the STEC strains of pediatric patients without diarrhea were lower than those with diarrhea. [Figure 1](#fig24446){ref-type="fig"} shows the total distribution of multi-drug resistance in the STEC strains of pediatric patients with and without diarrhea. All of the *E. coli* strains of pediatric patients with and without diarrhea harbored resistance against one antibiotic. We found that 65 out of 118 (55.08%) diarrheic and one out of 77 (1.29%) non-diarrheic *E. coli* isolates were resistant to more than six antibiotics.

###### Antibiotic Resistance Pattern of Shiga Toxigenic *Escherichia coli*Strains Isolated From Pediatric Patients With and Without Diarrhea^[a](#fn34873){ref-type="table-fn"}^

  Diarrhea Status and Age, mon   No. STEC Strains   Pattern of Antibiotic Resistance ^[b](#fn34872){ref-type="table-fn"}^                                                                                                                                                            
  ------------------------------ ------------------ ----------------------------------------------------------------------- ---------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ----------- ------------
  **Positive**                                                                                                                                                                                                                                                                       
  \< 1                           9                  6                                                                       \-         5            8            4            5            4            8            2            3            3            4            1           4
  11 - 21                        10                 6                                                                       1          5            9            3            4            5            9            2            3            3            3            1           4
  22 - 33                        7                  4                                                                       \-         3            6            2            2            3            7            1            2            2            2            1           2
  34 - 45                        7                  3                                                                       \-         3            6            2            2            3            6            1            1            3            2            1           2
  46 - 57                        6                  2                                                                       \-         2            5            1            2            2            6            1            2            1            1            1           2
  58 - 69                        4                  2                                                                       \-         1            3            1            1            1            4            \-           1            1            1            \-          1
  **Negative**                   12                 3                                                                       \-         3            6            3            3            2            6            1            2            3            3            1           2
  **Total**                      66                 33 (50)                                                                 1 (1.51)   27 (40.90)   52 (78.78)   18 (27.27)   23 (34.84)   25 (37.87)   56 (84.84)   11 (16.66)   17 (25.75)   20 (30.30)   20 (30.30)   8 (12.12)   22 (33.33)

^a^In this table: TE30: tetracycline (30 µg/disk); C30: chloramphenicol (30 µg/disk); SXT: sulfamethoxazole (25 µg/disk); GM10: gentamycin (10 µg/disk); CF30: cephalothin (30 µg/disk); CIP5: ciprofloxacin (5 µg/disk); TMP5: trimethoprim (5 µg/disk); AM10: ampicillin (10 µg/disk); COT25: co-trimoxazole (25 µg/disk); Cef30: cefotaxime (30 µg/disk); Cftr: ceftriaxone (30 µg/disk); Cfx5: cefixime (5 µg/disk); F/M300: nitrofurantoin (300 µg/disk); Nor10: norfloxacin (10 µg/disk) antimicrobial agents.

^b^ Value's unit is %.
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5. Discussion {#sec128413}
=============

The present investigation focused on the study of the prevalence of O-serogroups, virulence factors and antimicrobial resistance properties of STEC strains isolated from diarrheic and non-diarrheic pediatric patients with respect to age, seasonal and geographical distribution. We found that the 1 - 10 month old patients from the Shiraz during the summer season were the group at highest risk for infection with STEC strains. The main reason for the higher prevalence of *E. coli* in the summer season in Iran is the fact that during this time climatic events, heat, rain, and thunderstorms, as well as variation of barometric pressure may influence the autonomic nervous system. These events cause a reduction in the levels of human immunity. Therefore, several infections may occur. Furthermore, *E. coli* has better growth and surveillance in warm conditions. The levels of public and individual health are also decreased in warm climates, such as during summer. After analyzing the average temperatures of the four seasons in the study area (19°C for spring, 35°C for summer, 14°C for autumn and 5°C for winter), it was recognized that the prevalence of *E. coli* in each season was related to the average temperatures. A significant difference (P = 0.037) was seen between the average temperatures of hot and cold seasons. Similar researches have also reported on the seasonal distribution of *E. coli* infections ([@A29706R3], [@A29706R15]-[@A29706R18]). Available data between years 1996 and 2011, revealed the higher prevalence of *E. coli* infections during the hot months ([@A29706R18]). Higher prevalence of cases of gastrointestinal infections in the warm season of the year has also been reported previously ([@A29706R3], [@A29706R15]-[@A29706R18]). We also found that 1 - 10 month old pediatric patients were the most commonly infected group, which was similar to the results of Momtaz et al. ([@A29706R3]). They showed that 13 - 24 month old patients were the most infected age group (77.63%).

Our results revealed that the *E. coli* isolates of patients with diarrhea had a high prevalence of virulence factors. We found that the majority of *E. coli* strains harbored all *stx1*, *stx2* and *eaeA* genes together, indicating higher levels of pathogenicity and infection. The relatively high occurrence of the *stx1* gene compared to *stx2* in the diarrheic *E. coli* isolates suggests that *E. coli* carrying a combination of the *eaeA* and *stx1* genes is more common than the combination of *eaeA* and *stx2* genes. Some of the *E. coli* strains of our study harbored the *stx1*, *stx2* and *eaeA* genes together. The importance of these data lies in the fact that *eae*-positive strains are considered more virulent for humans than *eae*-negative strains, as well as strains carrying only the *stx2* genes ([@A29706R19]). This observation is of concern, as the former combination of genes is known to cause more severe diarrhea in humans ([@A29706R19]-[@A29706R21]). Momtaz et al. reported on the multiple presences of *stx1*, *eaeA* and *ehly* genes in the EHEC strains of one to 60 month old pediatric patients ([@A29706R3]). High presence of *stx1*, *stx2*, *eaeA* and *ehly* genes, in the *E. coli* isolates of diarrheic patients from Korea, Brazil, Australia and Kenya, has also been reported previously ([@A29706R21]-[@A29706R24]). Sang et al. showed that 37.1% of diarrheic patients were positive for *E. coli*, of which 24.1% were STEC ([@A29706R23]). Sang et al. reported that 52.9% of STEC isolates carried *stx1*, 29.4% possessed *stx2*, 14.7% carried both *stx1* and *stx2*, and 2.9% had *stx2e*, and 23.5% carried *ehly* and 20.5% of the isolates possessed the *eaeA* gene, which was similar to our results ([@A29706R23]).

Both O157 and non-O157 strains had a high prevalence in diarrheic pediatric patients of our investigation. On the other hand, O26 (33.33%), O111 (18.18%) and O91 (12.12%) were the most commonly detected O-serogroups in pediatric patients with and without diarrhea. In a study conducted in Iran, O26 (27.04%) had the highest incidence amongst STEC serogroups of diarrheic pediatrics, followed by O111 (18.85%) ([@A29706R3]). High prevalence of non-O157 serogroups of STEC strains in the cases of diarrhea has been reported by various studies ([@A29706R15]-[@A29706R17], [@A29706R25]). High prevalence of non-O157 strains and especially the O26 strain of STEC in the cases of diarrhea was reported from Germany ([@A29706R26]), Japan ([@A29706R27]) and South Africa ([@A29706R28]).

Extreme and highly irregular prescriptions of antimicrobial agents in our study area caused the high levels of resistance of STEC strains against ampicillin (84.84%), gentamycin (78.78%), tetracycline (50%) and sulfamethoxazole (40.90%) antibiotics. These high levels of resistance have been derived from the high presence of certain antibiotic resistance genes including *CITM* (80.30%), *aac (3)-IV* (75.75%) and *tetA* (65.15%). We also found that 55.08% of diarrheic and 1.29% of non-diarrheic *E. coli* isolates were resistant to more than six antibiotics, which was considerably high. We also recognized that O26 serogroup had the highest levels of antibiotic resistance and antibiotic resistance genes, which was similar to the results of Kijima-Tanaka et al. ([@A29706R27]) and Momtaz et al. ([@A29706R3]). Our results showed that the STEC strains of our study were also resistant to chloramphenicol (1.51%) and nitrofurantoin (12.12%) antibiotics.

Chloramphenicol and nitrofurantoin are forbidden antibiotics and the slight antibiotic resistance to these antimicrobial agents indicated their irregular and unauthorized use in medical treatment in Iran. Similarly, chloramphenicol and nitrofurantoin resistance have also been reported previously ([@A29706R3], [@A29706R29], [@A29706R30]). Another Iranian study ([@A29706R31]) showed that the STEC strains of diarrheic patients were resistant to amoxicillin (72.4%), trimethoprim-sulfamethoxazole (65.5%) and tetracycline (58.6%) antibiotics. Momtaz et al. ([@A29706R2]) reported that the STEC strains had the highest levels of resistance against sulfisoxazole (36%), tetracycline (32%), streptomycin (29%), ampicillin (10%), trimethoprim (8%), cotrimoxazole (8%), chloramphenicol (7%), kanamycin (7%), piperacillin (6%), and neomycin (5%) antibiotics, which was similar to our results.

In conclusion, we identified *E. coli* with defined pathotypes, which originated mainly from diarrheic and non-diarrheic pediatric patients of four major provinces of Iran. We also found a large number of virulent and resistant strains of *E. coli* with higher prevalence of *stx1* and *eaeA* genes, O26, O111 and O91 serogroups, CITM, *aac(3)-IV* and *tetA* antibiotic resistance genes and resistance to ampicillin, gentamycin, tetracycline and antibiotics. Shiraz due to its high temperature and moisture had the highest prevalence of *E. coli*. Simultaneous presence of *stx1* and *eaeA*, and *stx2* and *eaeA* virulence factors in some strains of *E. coli* in diarrheic children warned about an important public health problem. Prescription of co-trimoxazole, cefotaxime, cephalothin and ceftriaxone can be effective for treatment of the cases of infection due to STEC strains.
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